Item 5. Other Information

On May 15, 2025, Benjamin G. S. Fowke, III, a director of the Company, entered into a Rule 10b5-1 trading agreement (“Rule 10b5-1 Trading Plan”) intended to satisfy the affirmative defense conditions of Rule 10b5‑1(c) of the Securities Exchange Act of 1934. Mr. Fowke’s Rule 10b5-1 Trading Plan provides for an aggregate sale of up to 25,000 shares of common stock through December 12, 2025.

On May 15, 2025, Kelly J. Ferneau, the Executive Vice President and Chief Nuclear Officer of the Company, entered into a Rule 10b5-1 Trading Plan intended to satisfy the affirmative defense conditions of Rule 10b5‑1(c) of the Securities Exchange Act of 1934. Ms. Ferneau’s Rule 10b5-1 Trading Plan provides for an aggregate sale of up to 10,218 shares of common stock through February 23, 2026.

During the three months ended June 30, 2025, none of the Company’s directors or other officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) adopted, terminated or modified a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K of the Securities Act of 1933).